Polymer Capital Management (US) LLC
Position in AKBA — Akebia Therapeutics, Inc.
CIK 1973324
NEW YORK, NY
Position in AKBA
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$29,737
-$87,498 QoQ
Shares Held
21,394
-70.6% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Polymer Capital Management (US) LLC holds $2,411,560 across 7 Drug Manufacturers - Specialty & Generic names. AKBA ranks #7 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
6,290 | $828,644 | |
| 2 | VTRS |
Viatris Inc
|
33,324 | $450,207 | |
| 3 | ZTS |
Zoetis Inc.
|
3,757 | $444,114 | |
| 4 | INDV |
Indivior Pharmaceuticals, Inc.
|
8,240 | $251,155 | |
| 5 | BIOA |
BioAge Labs, Inc.
|
11,688 | $204,423 | |
| 6 | BCRX |
Biocryst Pharmaceuticals Inc
|
21,353 | $203,280 | |
| 7 | AKBA |
Akebia Therapeutics, Inc.
This page
|
21,394 | $29,737 |
All Filings in AKBA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,737 | 21,394 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $117,235 | 72,817 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $49,773 | 18,232 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $44,400 | 12,198 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||